Healio Minute

In this edition, AYA cancer survivors are at higher risk for death due to second primary cancers; a radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer; a phase 3 trial of tiragolumab plus atezolizumab misses its co-primary endpoint; and more.

Read the full coverage here:

AYA cancer survivors at higher risk for death due to second primary cancers

Radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer

Phase 3 trial of combination for advanced lung cancer misses co-primary endpoint

As proton beam therapy use for cancer increased, 'so did the racial disparity in receipt'

Entrectinib induces durable, intracranial responses in NTRK fusion-positive solid tumors

References:

Sung H, et al. J Natl Cancer Inst. 2022;doi:10,1093/jnci/djac091.

Louie AV, et al. JAMA Oncol. 2022:doi:10.1001/jamaoncol.2021.7664.

Press Release

Nogueira LM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.8970.

Demetri GD, et al. Clin Cancer Res. 2022;doi:10.1158/1078-0432.CCR-21-3597.

In this week's edition, anxiety, depression worse among older men with vision impairment; emerging therapeutics may improve outcomes in pediatric patients with rare disorders; glioblastoma presents roadblock to successful immunotherapy; and more.

Read the full coverage here:

MRI findings key pathology markers of 4R-tauopathies

Emerging therapeutics may improve outcomes in pediatric patients with rare disorders

Together Senior Health launches platform to reduce memory loss in AD, dementia

Anxiety, depression worse among older men with vision impairment

Glioblastoma presents roadblock to successful immunotherapy

References:

Carlos AF, et al. Tau histopathological lesion type correlates of structural magnetic resonance imaging and diffusion tensor imaging biomarkers in 4-repeat tauopathies. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Emrick L, et al. Emerging therapeutics for rare pediatric genetic disorders. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Press Release

Gascoyne B, et al. Int Health. 2022;doi:10.1093/inthealth/ihab070

Kumthekar P. AAN year in review: neuro oncology. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Read the full coverage here:

In this edition, diet, genetics and family history play role in AMD progression; omega-3 fatty acids may improve vision in dry AMD; long-term dopamine treatment may delay onset of diabetic retinopathy; and more.

Diet, genetics and family history play role in AMD progression

Omega-3 fatty acids may improve vision in dry AMD

Long-term dopamine treatment may delay onset of diabetic retinopathy

Anti-VEGF injections decrease aqueous VEGF levels in diabetic retinopathy

Novel ERG method aids in monitoring patients with posterior uveitis

References:

Williams BK. What to do for your patient with early dry AMD. Presented at: American Society of Cataract and Refractive Surgery meeting; April 22-26, 2022; Washington.

Prokopiou E, et al. A prospective, randomised, multicenter, double-blind, placebo-controlled study assessing the potential effects of omega-3 fatty acids supplementation on dry age-related macular degeneration and Stargardt disease. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Allen RS, et al. Dopamine treatment delays diabetic retinopathy onset in a retrospective study. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Mynampati BK, et al. Aqueous levels of VEGF decrease after serial intravitreal injections of anti-VEGF agents in patients with diabetic retinopathy. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Than NTT, et al. Flicker ERG findings in posterior uveitis. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

In this week's edition, childhood sexual and emotional abuse increases the risk for multiple sclerosis in women; fentanyl-related cardiac arrest is linked to worse neurological outcomes; Black patients with MS have a higher rate of disability compared with their white counterparts; and more.

Read the full coverage here:

Childhood sexual, emotional abuse increases multiple sclerosis risk in women

Fentanyl-related cardiac arrest linked to worse neurological injury, outcomes

Black MS patients have higher rate of disability than white counterparts

Brain stimulation software receives FDA approval for use in Parkinson's disease

Seizure frequency, poor quality of life risk factors for depression in epilepsy patients

References:

Eid K, et al. J Neurol Neurosurg Psychiatry. 2022;doi:10.1136/jnnp-2021-328700.

Otero M, et al. Neurological injury and outcomes in fentanyl-related cardiac arrest. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Dykes E, et al. Health disparities in African American patients with multiple sclerosis: a retrospective chart-review study. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Press Release

Syed M, et al. Factors associated with depression in epilepsy patients: a population-based study in the Detroit metropolitan area. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

In this edition, early lung cancer detection improves survival rates; incidental respiratory findings on low-dose CT lung cancer screening common; certain patients may derive more benefit from immunotherapy for non-small cell lung cancer and more.

Read the full coverage here:

Early lung cancer detection improves survival rates

Incidental respiratory findings on low-dose CT lung cancer screening common

Certain patients may derive more benefit from immunotherapy for non-small cell lung cancer

Bispecific antibody shows durable benefit in advanced solid tumors

Enhertu receives priority review for HER2-mutated non-small cell lung cancer

References:

Healio Interview

Pinsky PF, et al. Chest. 2022;doi:10.1016/j.chest.2021.11.015.

Patel K, et al. JNCI Cancer Spectr. 2022;doi:10.1093/jncics/pkac015

Bispecific antibody shows durable benefit in advanced solid tumors

Press Release

In this week's edition, risk for cognitive decline is associated with older COVID-19 survivors; a study validates an FDA-approved blood test for traumatic brain injury; and more.

Read the full coverage here:

Risk for cognitive decline associated with older COVID-19 survivors

Study validates FDA-approved blood test for traumatic brain injury

VA hospital telestroke networks improve treatment, lower ED transfer rate

Lower left atrial function associated with higher risk for dementia

Rates of neurological events higher with SARS-CoV-2 infection than with COVID-19 vaccine

References:

Liu YH, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.0461.

Papa L, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.1302.

Lyerly M, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200143.

Wang W, et al. JAMA. 2022;doi:10.1001/jama.2022.2518

Li X, et al. BMJ. 2022;doi:10.1136/bmj-2021-068373.

In this edition, European commission approves Beovu for DME, choroidal vascularity index linked with geographic atrophy progression, intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy, and more.

Read the full coverage here:

Susvimo noninferior to monthly ranibizumab with similar efficacy

European Commission approves Beovu for DME

Intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy

Teprotumumab may provide better outcomes than IV methylprednisolone in thyroid eye disease

Choroidal vascularity index linked with geographic atrophy progression

References:

Healio Interviews

Holekamp NM, et al. Ophthalmology. 2022;doi:10.1016/j.ophtha.2021.09.016.

Newman N, et al. The Phase III REFLECT Trial: Efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy (LHON). Presented at: American Academy of Neurology Annual Meeting; April 2-7, 2022; Seattle.

Press Release

Sacconi R, et al. Retina. 2022;doi:10.1097/IAE.0000000000003305.

In this week's edition, the FDA approval of an oral anticonvulsant; plus news you may have missed from the AAN and ACTRIMS meetings.

Read the full coverage here:

FDA approves oral anticonvulsant

New drug improved tic severity in children with Tourette syndrome

Vitamin D levels not associated with adverse outcomes in European MS patients

Zolpidem may be effective for prolonged disorders of consciousness

Amygdala overgrowth begins in first year of life in infants with ASD

References:

Press Release

Gilbert DL, et al. ES1.002: Ecopipam in children and adolescents with Tourette syndrome: Results from a randomized, double-blind, placebo-controlled phase 2b study. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Vasileiou E, et al. Vitamin D polygenic score and multiple sclerosis outcomes. Presented at: ACTRIMS Forum; Feb. 24-26; West Palm Beach, Florida.

Cassidy J, et al. Impact of zolpidem in the treatment of prolonged disorders of consciousness. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Shen MD, et al. Am J Psychiatry. 2022;doi:10.1176/appi.ajp.21090896

Disclosures: Please see each study for relevant financial disclosures.

In this edition, digital imaging and AI advance investigation of systemic disease through the retina; handheld retinal imaging devices may have utility in screening; Xipere launches in the US; and more.

Read the full coverage here:

Digital imaging, AI advance investigation of systemic disease through the retina

No additional visual benefit seen with nesvacumab-aflibercept combination in DME

Soft drusen, subretinal drusenoid deposits may be separate diseases leading to AMD

Xipere launches in US

Handheld retinal imaging devices may have utility in screening

References:

Healio Interviews

Brown DM, et al. Retina. 2022;doi:10.1097/IAE.0000000000003441.

Thomson RJ, et al. Retina. 2022;doi:10.1097/IAE.0000000000003460.

Press Release

Salongcay RP, et al. Ophthalmol Retina. 2022;doi:10.1016/j.oret.2022.03.002

In this edition, a phase 3 trial of a regimen for small cell lung cancer misses its co-primary endpoint; obesity and pulmonary function may identify the need for home oxygen after lung cancer surgery; a study finds that lung cancer screening is less common among those most likely to benefit from it; and more.

Read the full coverage here:

Phase 3 trial of regimen for small cell lung cancer misses co-primary endpoint

Obesity, pulmonary function may identify need for home oxygen after lung cancer surgery

Lung cancer screening less common among those most likely to benefit from it

FDA rejects sintilimab with chemotherapy for non-small cell lung cancer

Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC

References:

Press Release

Nicastri DG, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202103-231OC.

Rustagi AS, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.5318.

Press Release

Rajakumar T, et al. npj Precis Oncol. 2022;doi:10.1038/s41698-022-00262-y.